Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IoM Sets Vitamin D Intake Levels Below Experts' Expectations

This article was originally published in The Tan Sheet

Executive Summary

The Institute of Medicine sets its daily vitamin D daily allowance well below the amounts some nutrition experts suggest.

You may also be interested in...



AHRQ Vitamin D/Calcium Report Draws Industry Fire

The U.S. Preventive Service Task Force releases a meta-analysis looking at whether available research supports an association between the use of vitamin D and calcium and fracture prevention. Trials of vitamin D use alone or with calcium showed no statistically significant reduction in fractures among subjects in the control groups, the panel found.

AHRQ Vitamin D/Calcium Report Draws Industry Fire

The U.S. Preventive Service Task Force releases a meta-analysis looking at whether available research supports an association between the use of vitamin D and calcium and fracture prevention. Trials of vitamin D use alone or with calcium showed no statistically significant reduction in fractures among subjects in the control groups, the panel found.

FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules

FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel